Shares of Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) saw an uptick in trading volume on Friday . 461,269 shares traded hands during mid-day trading, an increase of 65% from the previous session’s volume of 278,931 shares.The stock last traded at $16.29 and had previously closed at $16.27.

Several brokerages recently commented on AMPH. BMO Capital Markets began coverage on Amphastar Pharmaceuticals in a research report on Tuesday, June 28th. They issued a “market perform” rating and a $17.00 target price for the company. Zacks Investment Research cut Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday. TheStreet raised Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, April 14th. Finally, Needham & Company LLC reduced their target price on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, May 10th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $16.80.

The company has a market capitalization of $725.59 million and a PE ratio of 8090.00. The stock has a 50-day moving average of $16.39 and a 200-day moving average of $13.53.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Monday, May 9th. The company reported $0.12 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.03) by $0.15. The company had revenue of $59.40 million for the quarter, compared to analyst estimates of $62 million. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.01) EPS. Equities research analysts anticipate that Amphastar Pharmaceuticals Inc. will post $0.12 EPS for the current fiscal year.

In related news, Director Richard K. Prins sold 3,200 shares of the business’s stock in a transaction that occurred on Tuesday, May 17th. The stock was sold at an average price of $13.56, for a total transaction of $43,392.00. Following the transaction, the director now directly owns 23,000 shares of the company’s stock, valued at approximately $311,880. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO William J. Peters sold 2,297 shares of the business’s stock in a transaction that occurred on Monday, July 18th. The stock was sold at an average price of $17.76, for a total value of $40,794.72. Following the transaction, the chief financial officer now directly owns 64,652 shares in the company, valued at $1,148,219.52. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Amphastar Pharmaceuticals stock. Russell Frank Co raised its position in Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) by 289.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 83,965 shares of the company’s stock after buying an additional 62,407 shares during the period. Russell Frank Co owned about 0.19% of Amphastar Pharmaceuticals worth $1,204,000 as of its most recent filing with the SEC.

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.